PUBLISHER: The Business Research Company | PRODUCT CODE: 1877585
PUBLISHER: The Business Research Company | PRODUCT CODE: 1877585
A continuous bio-manufacturing skid is a compact, pre-assembled system designed to enable the continuous production of biologics by integrating unit operations such as fermentation, purification, and formulation into a seamless workflow. It provides automated, scalable, and efficient biomanufacturing while reducing manual intervention and process variability.
The main product categories of continuous bio-manufacturing skids include single-use skids, multi-use skids, and modular skids. Single-use skids are fully integrated disposable systems designed for uninterrupted biologics production, where all product-contact components are single-use to minimize cross-contamination and cleaning requirements while supporting continuous upstream or downstream processing. These skids are used for various processes, including upstream, downstream, and integrated operations. They are applied in biopharmaceutical production, vaccine manufacturing, enzyme production, cell and gene therapy, and other areas, serving a wide range of end users such as pharmaceutical companies, biotechnology companies, contract manufacturing organizations, research institutes, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The continuous bio-manufacturing skid market research report is one of a series of new reports from The Business Research Company that provides continuous bio-manufacturing skid market statistics, including continuous bio-manufacturing skid industry global market size, regional shares, competitors with a continuous bio-manufacturing skid market share, detailed continuous bio-manufacturing skid market segments, market trends and opportunities, and any further data you may need to thrive in the continuous bio-manufacturing skid industry. This continuous bio-manufacturing skid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The continuous bio-manufacturing skid market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.99 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. Growth during the historic period can be attributed to the increasing demand for biologics production, growing adoption of automated bioprocessing systems, rising investments in process intensification technologies, greater awareness of time-to-market reduction benefits, and the growing emphasis on regulatory compliance and traceability.
The continuous bio-manufacturing skid market size is expected to see rapid growth in the next few years. It will grow to $3.29 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. Growth in the forecast period can be attributed to the increasing demand for personalized medicine, rising need for scalable and modular manufacturing platforms, growing investments in emerging markets for biologics, increasing focus on green and sustainable production methods, and expanding digitalization and smart manufacturing. Key trends during the forecast period include technological advancements in process automation, innovations in skid design, progress in modular bioprocessing, research and development in continuous manufacturing, and integration of digital monitoring solutions.
The growing demand for biopharmaceuticals is expected to boost the growth of the continuous bio-manufacturing skid market in the coming years. Biopharmaceuticals are medicinal products derived from biological sources such as proteins, nucleic acids, or living cells and are used to treat, prevent, or diagnose various diseases. The increasing demand for biopharmaceuticals is primarily driven by the rising prevalence of chronic and genetic disorders that require advanced biologic therapies for effective treatment and management. Continuous bio-manufacturing skids enhance biopharmaceutical production by offering automated, scalable, and streamlined processes that improve efficiency, consistency, and production speed for complex therapies. For example, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the United States had 40 FDA-approved biosimilar products, with 25 available on the market. In comparison, as of January 2022, there were 33 FDA-approved biosimilars, of which 21 were commercially available. Therefore, the increasing demand for biopharmaceuticals is driving the growth of the continuous bio-manufacturing skid market.
Leading companies in the continuous bio-manufacturing skid market are developing advanced solutions such as next-generation biologics manufacturing platforms to enhance production efficiency, scalability, and product quality. These next-generation biologics platforms are advanced systems designed to enable fully connected, continuous biologics production with real-time monitoring, improved productivity, and consistent output quality. For instance, in October 2024, Enzene Biosciences Ltd., an India-based contract development and manufacturing organization, launched EnzeneX 2.0 at CPHI Milan 2024, the next generation of its fully connected continuous manufacturing (FCCM) technology for biologics. This patented system allows seamless, uninterrupted processing from perfusion to the final drug substance. By using high-titer clones and optimized cell media, it increases productivity, enhances protein concentration, and reduces batch-to-batch variation. It also integrates process analytical technology for real-time control and monitoring, ensuring high quality and operational efficiency while reducing production costs by up to 50% per gram. These platforms offer scalable, cost-effective biologics manufacturing adaptable to a variety of modalities and formulations.
In June 2023, Donaldson Company Inc., a US-based filtration technology company, acquired Univercells Technologies for $159 million (€136 million). The acquisition aims to expand Donaldson's life sciences portfolio by incorporating Univercells Technologies' innovative single-use bioreactors and automated upstream platforms to deliver advanced biomanufacturing solutions for cell and gene therapies, vaccines, and other biologics. Univercells Technologies S.A. is a Belgium-based company that provides advanced biomanufacturing systems featuring intensified and integrated continuous processing technologies.
Major players in the continuous bio-manufacturing skid market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Garrett Industrial Systems Ltd., Sartorius AG, Getinge AB, ZETA GmbH, Pall Corporation, Repligen Corporation, ABEC Inc., Enzene Biosciences Limited, Pierre Guerin Technologies, Bioengineering AG, KeyPlants GmbH, G&G Technologies Pvt. Ltd., Scigenics Pvt. Ltd, Exentec B.V., PAK BioSolutions Inc., Stobbe Pharma GmbH, and CPi Biotech Inc.
North America was the largest region in the continuous bio-manufacturing skid market in 2024. The regions covered in continuous bio-manufacturing skid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the continuous bio-manufacturing skid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The continuous bio-manufacturing skid market consists of sales of bioprocessing equipment, monitoring and control systems, sensors, pumps, tubing assemblies, valves, mixing systems, and control panels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Continuous Bio-Manufacturing Skid Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on continuous bio-manufacturing skid market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for continuous bio-manufacturing skid ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The continuous bio-manufacturing skid market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.